By Scienceable Staff
A significant advancement in psychiatric diagnostics has emerged with the development of a rapid, blood-based test that can accurately distinguish between schizophrenia (SZ) and bipolar disorder (BD), two of the most difficult-to-differentiate severe mental illnesses. The test, pioneered by Laguna Diagnostics, LLC, promises to cut the diagnosis time from years to mere days, delivering results with an accuracy exceeding 90%.
The Current Diagnostic Crisis
Schizophrenia and bipolar disorder affect millions globally, yet their overlapping symptomology makes accurate clinical distinction a monumental challenge. Current diagnostic processes rely heavily on subjective assessments, patient self-reporting, and long-term observation, often requiring one to three years to reach a final conclusion. This protracted and inexact approach leads to alarmingly high rates of misdiagnosis, with estimates suggesting 50% of schizophrenia and 70% of bipolar disorder cases are initially identified incorrectly. This delay and error severely postpone effective, tailored treatment.
The Sentinel Principle: Blood as a Brain Mirror
The breakthrough is rooted in the concept of the “sentinel principle,” which posits that circulating blood reflects the health and pathology of the entire body, including the brain. The test utilizes a panel of precision biomarker signatures that measure the messenger RNA (mRNA) expression levels of 18 specific genes found in the blood.
Researchers found that the unique transcriptional patterns—the way these 18 genes are expressed—differ consistently between healthy individuals, those with schizophrenia, and those with bipolar disorder.
The method employs a four-step process to calculate the probability that a blood sample comes from a patient with Schizophrenia (SZ), Bipolar Disorder (BD), or a psychiatrically normal individual (NC). The foundational peer-reviewed research demonstrated that these 18-gene biomarker panels could differentiate the three groups with an initial accuracy ranging from 88% to 96%.
Transforming Clinical Practice
The ability to obtain objective, reliable results in days, rather than years, holds profound implications for clinical psychiatry:
- Earlier Intervention: A rapid and precise diagnosis allows physicians to initiate disorder-specific treatment much sooner, which is crucial for improving long-term outcomes for severe mental illnesses.
- Reduced Misdiagnosis: By moving away from subjective observation, the high rate of misdiagnosis can be drastically reduced, preventing patients from enduring years of ineffective or potentially harmful treatment paths.
- Objective Metric: The test provides a quantitative, objective biological metric, a tool that has been missing from mental healthcare, offering a new standard for patient care.
The company has recently been awarded its second U.S. patent for this technology and is preparing for FDA clinical validation trials.
“Our technology not only differentiates between bipolar disorder and schizophrenia… but also has broad potential to diagnose and differentiate other mental illnesses, truly revolutionizing the field of psychiatry and giving physicians tools they have never had before,” stated Terry W. Osborn, PhD, MBA, Co-Founder and Chief Executive Officer of Laguna Diagnostics.
Source:
The diagnostic method is built upon the following peer-reviewed publication:
Vawter, M. P., Philibert, R., Rollins, B., Ruppel, P. L. and Osborn, T. W. (2018) Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder. Molecular Neuropsychiatry, 3: 197–213.
